3.49  -0.33 (-8.64%)		10-24 16:00
Open: 3.93 High: 5.86 Volume: 18,399,289		Pre. Close: 3.82 Low: 3.31 Market Cap: 34(M)

Short term
Mid term
Targets	6-month :	5.34	1-year :	6.84
Resists	First :	4.57	Second :	5.86
Pivot price	3.28
Supports	First :	2.49	Second :	2.07
MAs	MA(5) :	3.68	MA(20) :	3.25
	MA(100) :	2.66	MA(250) :	2.55
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	66.4	D(3) :	80.9
RSI	RSI(14): 57.8
52-week	High :	6.19	Low :	1.33

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NRXS ] has closed below upper band by 37.5%. Bollinger Bands are 110.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	5.86 - 5.89	5.89 - 5.91
Low:	3.27 - 3.29	3.29 - 3.31
Close:	3.41 - 3.44	3.44 - 3.46

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Fri, 24 Oct 2025
NeurAxis, Inc. (NRXS) Stock: Plunges Despite FDA Clearance Breakthrough for Adult Functional Dyspepsia Treatment - parameter.io

Fri, 24 Oct 2025
NeurAxis Expands Stock Offering to $6.27 Million - TipRanks

Fri, 24 Oct 2025
Neuraxis Receives FDA Clearance for PENFS Technology - TradingView

Fri, 24 Oct 2025
NeurAxis (NYSE American: NRXS) secures 510(k) clearance for FD pain, ages 8+ - Stock Titan

Fri, 24 Oct 2025
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire

Thu, 23 Oct 2025
Neuraxis reports preliminary Q3 2025 financial results with $2.1 million operating loss - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	3 (M)
Held by Insiders	51.2 (%)
Held by Institutions	1.6 (%)
Shares Short	12 (K)
Shares Short P.Month	7 (K)

EPS	-2.24
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.77
Profit Margin	0 %
Operating Margin	-360.9 %
Return on Assets (ttm)	-260.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-5.4 %
Gross Profit (p.s.)	0
Sales Per Share	0.33
EBITDA (p.s.)	-1.27
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-1.55
PEG Ratio	0
Price to Book value	-4.47
Price to Sales	10.36
Price to Cash Flow	-2.81

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.